EGFR and colorectal carcinoma: Another biomarker that is part of the same EGFR signaling pathway as KRAS that has been investigated for predicting response to EGFR monoclonal antibody treatment in CRC is the v-raf murine sarcoma viral oncogene homolog B, known as BRAF[14], [15].The BRAF gene sequence variant p.Val600Glu, often called V600E, is the main sequence variant in this gene that is associated with CRC[16].